• Something wrong with this record ?

Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy

M Beranek, P Kolar, S Tschoplova, K Kankova, A Vasku

. 2008 ; 14 (1) : 1114-1121.

Language English Country United States

PURPOSE: Matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. METHODS: The study comprised 490 Caucasian participants, who were divided into three groups: diabetics with PDR, diabetics without PDR, and nondiabetics. Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined. Plasma levels of MMP-2 and MMP-9 proteins were analyzed by ELISA. RESULTS: Neither MMP-2 SNPs nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differ notably between groups, although the C-allele of the -1306C/T polymorphism and the C-allele containing haplotype (CGCG) in MMP-2 exhibited marginally significant association with PDR in males (p<0.05, p(corr)=NS). Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were markedly higher in carriers of either the -1306CC and -1306CT genotypes and (p=0.009) or CGCG haplotype (p=0.043). CONCLUSIONS: These findings indicate that genotype- and haplotype-specific effects on MMP-2 expression corresponding with its plasma levels may contribute to the susceptibility to PDR.

000      
02114naa 2200457 a 4500
001      
bmc11003964
003      
CZ-PrNML
005      
20121221105501.0
008      
110303s2008 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Beránek, Michal. $7 xx0193695
245    10
$a Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy / $c M Beranek, P Kolar, S Tschoplova, K Kankova, A Vasku
314    __
$a Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. mberanek@med.muni.cz
520    9_
$a PURPOSE: Matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. METHODS: The study comprised 490 Caucasian participants, who were divided into three groups: diabetics with PDR, diabetics without PDR, and nondiabetics. Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined. Plasma levels of MMP-2 and MMP-9 proteins were analyzed by ELISA. RESULTS: Neither MMP-2 SNPs nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differ notably between groups, although the C-allele of the -1306C/T polymorphism and the C-allele containing haplotype (CGCG) in MMP-2 exhibited marginally significant association with PDR in males (p<0.05, p(corr)=NS). Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were markedly higher in carriers of either the -1306CC and -1306CT genotypes and (p=0.009) or CGCG haplotype (p=0.043). CONCLUSIONS: These findings indicate that genotype- and haplotype-specific effects on MMP-2 expression corresponding with its plasma levels may contribute to the susceptibility to PDR.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a diabetická retinopatie $x enzymologie $x genetika $x patologie $7 D003930
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická variace $7 D014644
650    _2
$a haplotypy $7 D006239
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a matrixová metaloproteinasa 2 $x genetika $x krev $7 D020778
650    _2
$a matrixová metaloproteinasa 9 $x genetika $x krev $7 D020780
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pohlavní dimorfismus $7 D012727
650    _2
$a financování organizované $7 D005381
700    1_
$a Kolář, Petr, $d 1970- $7 xx0037722
700    1_
$a Tschöplová, Svatava. $7 _AN033174
700    1_
$a Kaňková, Kateřina, $d 1971- $7 mzk2003190820
700    1_
$a Vašků, Anna, $d 1954- $7 mzk2006356130
773    0_
$t Molecular Vision $w MED00008305 $g Roč. 14, č. 1 (2008), s. 1114-1121
910    __
$a ABA008 $b x $y 6
990    __
$a 20110413110159 $b ABA008
991    __
$a 20121221105545 $b ABA008
999    __
$a ok $b bmc $g 831304 $s 695988
BAS    __
$a 3
BMC    __
$a 2008 $b 14 $c 1 $d 1114-1121 $m Molecular vision $n Mol Vis $x MED00008305
LZP    __
$a 2011-3B/irme

Find record